A Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Gout

Trial Profile

A Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Gout

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Diacerein (Primary) ; Febuxostat
  • Indications Gout
  • Focus Proof of concept; Therapeutic Use
  • Sponsors TWi Biotechnology
  • Most Recent Events

    • 08 Nov 2017 Primary endpoint of proportion of subjects achieving serum uric acid concentration 6.0 mg/dL has been met, according to results presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
    • 08 Nov 2017 Results presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
    • 01 Nov 2017 According to a TWi Biotechnology media release, data will be presented at the 2017 ACR/ARHP annual meeting in San Diego.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top